Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Monday, 01'st Jun 2026
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AUTL's 50-day simple moving average br
Autolus Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 27'th May 2026
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gene
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
05:10pm, Thursday, 21'st May 2026
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gener
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
08:10pm, Thursday, 14'th May 2026
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
Autolus Therapeutics Q1 Earnings Call Highlights
10:09am, Thursday, 14'th May 2026
Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year re
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
07:00am, Thursday, 14'th May 2026
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quarter of 2026, reflecting strong launches in the US and most recently the UK Company achieves positiv
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
07:00am, Tuesday, 05'th May 2026
LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-gener
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
04:05pm, Wednesday, 29'th Apr 2026
Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commerc
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:10pm, Tuesday, 21'st Apr 2026
LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen
Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data
02:03am, Friday, 10'th Apr 2026
Autolus Therapeutics (NASDAQ: AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicians and investigators who discussed the treatment landscape, re
Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
Autolus Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 07'th Apr 2026
LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-gen
Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
02:56pm, Friday, 27'th Mar 2026
Autolus Therapeutics plc maintains a Hold rating due to a challenging risk/reward profile despite strong clinical data for Aucatzyl in r/r B-ALL. 2026 guidance targets $120–$135m in product revenues
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
02:25pm, Friday, 27'th Mar 2026
Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
07:00am, Friday, 27'th Mar 2026
AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successfu
